Celladon Corp (CLDN) 10.48 $CLDN
Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
Nasdaq stocks posting largest percentage increases
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why You Shouldn't Bet Against Celladon Corporation (CLDN) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:57AM CDT
Celladon is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose over 11% on the day.
5 Stocks Moving on Unusual Volume
at The Street - Tue Aug 19, 6:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Celladon Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Mon Aug 18, 3:05PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the closing of its underwritten public offering of 4,600,000 shares of its common stock at $9.50 per share, including 600,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of $43.7 million before deducting underwriting discounts and commissions and other offering expenses payable by Celladon.
Nasdaq stocks posting largest volume increases
AP - Thu Aug 14, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Celladon (CLDN) Falls: Stock Goes Down 6.2% - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Wed Aug 13, 7:30AM CDT
Celladon stock fell over 6% last trading session, continuing its recent downtrend
Celladon Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Aug 12, 5:06PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at $9.50 per share. The gross proceeds to Celladon from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Celladon, are expected to be approximately $38.0 million. Celladon has also granted the underwriters a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock. The offering is scheduled to close on August 18, 2014, subject to customary closing conditions.
Celladon Announces Initiation of Clinical Trial to Investigate MYDICAR in Patients With Heart Failure and a Left Ventricular Assist Device (LVAD)
GlobeNewswire - Mon Aug 11, 3:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that the first patient has been dosed in a clinical trial titled "Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients with Heart Failure and a Left Ventricular Assist Device (LVAD)," which is designed to assess the potential utility of MYDICAR in advanced heart failure patients whose hearts are being supported by LVADs. This trial is partially funded by the British Heart Foundation and sponsored by Imperial College London.
Celladon Reports Second Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Thu Aug 07, 5:31AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced financial results for the quarter ended June 30, 2014 and recent highlights.
Celladon Announces Commencement of Public Offering of Common Stock
GlobeNewswire - Thu Aug 07, 5:30AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it is offering to sell 4,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Celladon will also grant to the underwriters a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Celadon Group Reports June Quarter And Full Fiscal Year Results And Declares Dividend
PR Newswire - Wed Aug 06, 4:06PM CDT
Celadon Group Inc. (NYSE: CGI) today reported its financial and operating results for the three months and fiscal year ended June 30, 2014, the fourth fiscal quarter of the Company's fiscal year ending June 30, 2014.
Celladon Corporation Secures $25 Million Credit Facility From Hercules Growth Capital
GlobeNewswire - Fri Aug 01, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it has entered into a credit facility with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) and its affiliate lenders. The credit facility provides for up to $25 million of loans.
Celladon to Report Second Quarter 2014 Results on August 7, 2014
GlobeNewswire - Wed Jul 30, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it will report its results for the second quarter ended June 30, 2014 on Thursday, August 7, 2014. The company will also hold a live investor conference call and webcast at 8:30am Eastern/5:30am Pacific on Thursday, August 7, 2014.
Celladon Corporation Announces In-License of Stem Cell Factor Development Program
GlobeNewswire - Mon Jul 21, 6:09AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation today announced an exclusive, global license from Enterprise Partners Venture Capital for gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia. Stem Cell Factor is a critical cytokine which contributes to cell migration, proliferation, and survival of cardiac stem cells.
Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
Nasdaq stocks posting largest percentage increases
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why You Shouldn't Bet Against Celladon Corporation (CLDN) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:57AM CDT
Celladon is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose over 11% on the day.
5 Stocks Moving on Unusual Volume
at The Street - Tue Aug 19, 6:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Celladon Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Mon Aug 18, 3:05PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the closing of its underwritten public offering of 4,600,000 shares of its common stock at $9.50 per share, including 600,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of $43.7 million before deducting underwriting discounts and commissions and other offering expenses payable by Celladon.
Nasdaq stocks posting largest volume increases
AP - Thu Aug 14, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Celladon (CLDN) Falls: Stock Goes Down 6.2% - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Wed Aug 13, 7:30AM CDT
Celladon stock fell over 6% last trading session, continuing its recent downtrend
Celladon Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Tue Aug 12, 5:06PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at $9.50 per share. The gross proceeds to Celladon from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Celladon, are expected to be approximately $38.0 million. Celladon has also granted the underwriters a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock. The offering is scheduled to close on August 18, 2014, subject to customary closing conditions.
Celladon Announces Initiation of Clinical Trial to Investigate MYDICAR in Patients With Heart Failure and a Left Ventricular Assist Device (LVAD)
GlobeNewswire - Mon Aug 11, 3:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that the first patient has been dosed in a clinical trial titled "Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients with Heart Failure and a Left Ventricular Assist Device (LVAD)," which is designed to assess the potential utility of MYDICAR in advanced heart failure patients whose hearts are being supported by LVADs. This trial is partially funded by the British Heart Foundation and sponsored by Imperial College London.
Celladon Reports Second Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Thu Aug 07, 5:31AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced financial results for the quarter ended June 30, 2014 and recent highlights.
Celladon Announces Commencement of Public Offering of Common Stock
GlobeNewswire - Thu Aug 07, 5:30AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it is offering to sell 4,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Celladon will also grant to the underwriters a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Celadon Group Reports June Quarter And Full Fiscal Year Results And Declares Dividend
PR Newswire - Wed Aug 06, 4:06PM CDT
Celadon Group Inc. (NYSE: CGI) today reported its financial and operating results for the three months and fiscal year ended June 30, 2014, the fourth fiscal quarter of the Company's fiscal year ending June 30, 2014.
Celladon Corporation Secures $25 Million Credit Facility From Hercules Growth Capital
GlobeNewswire - Fri Aug 01, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it has entered into a credit facility with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) and its affiliate lenders. The credit facility provides for up to $25 million of loans.
Celladon to Report Second Quarter 2014 Results on August 7, 2014
GlobeNewswire - Wed Jul 30, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it will report its results for the second quarter ended June 30, 2014 on Thursday, August 7, 2014. The company will also hold a live investor conference call and webcast at 8:30am Eastern/5:30am Pacific on Thursday, August 7, 2014.
Celladon Corporation Announces In-License of Stem Cell Factor Development Program
GlobeNewswire - Mon Jul 21, 6:09AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation today announced an exclusive, global license from Enterprise Partners Venture Capital for gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia. Stem Cell Factor is a critical cytokine which contributes to cell migration, proliferation, and survival of cardiac stem cells.
